Added to YB: 2026-05-21
Pitch date: 2026-05-18
QURE [bullish]
uniQure N.V.
-0.75%
current return
Author Info
Triple S is a professional special situations investor who shares ideas in their newsletter. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.6B
Pitch Price
$24.79
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.10
P/E
-7.15
EV/Sales
84.64
Sector
Biotechnology
Category
growth
Stock Trade Compilation Episode Siete - uniQure N.V.
QURE: Building stock + selling $45 calls at $12 (net cost $15). EU product revenue backstop mid-teens in 2027 post-UK approval. US regulatory upside if Makary replacement more favorable to gene therapy. Epilepsy drug readout later 2025 not priced in. Optimistic on new CBER head Karim Mikhail.
Read full article (1 min)